SAMIL PHARM to issue Convertible Bonds
삼일제약
000520
Signal Score
Historical Avg Return (5d)
+0.38%
Data Coverage
100%n=2330
Risk-adjusted indicator based on 2330 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Put Option: Exercisable from June 19, 2028, every 3 months
- • Call Option: Exercisable from June 19, 2027, every 3 months (5 times)
- • Call Option Limit: Up to 35% of total CB issuance amount
AI Analysis Summary
SAMIL PHARM has decided to issue convertible bonds. The report details the terms of the put and call options. The put option is exercisable from June 19, 2028, every three months, with a 0.0% early redemption yield. The call option is exercisable from June 19, 2027, every three months for a total of five times, with a redemption price applying an annual rate of 0.1% (3-month compound interest). The call option exercise is limited to 35% of the total CB issuance amount. Specific details regarding the total amount, conversion price, and number of shares to be issued upon conversion are not provided in the current disclosure, making a full dilution analysis impossible. The purpose of the funds is also not specified. This issuance could lead to future dilution if converted, but the immediate impact is neutral given the lack of specific financial figures.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.